 Improvement insulin-induced glucose disposal obese patients NIDDM treatment d-fenfluramine OBJECTIVE short-term effects serotoninergic anorectic drug d-fenfluramine insulin-induced glucose disposal RESEARCH DESIGN AND METHODS randomized double-blind placebo-controlled crossover trial treatment periods mg/day d-fenfluramine obese subjects normal oral glucose tolerance non-insulin-dependent diabetes NIDDM weight-maintaining diet Euglycemic-hyperinsulinemic glucose clamps measurement glucose kinetics D- patients NIDDM patients NIDDM insulin delivery rates RESULTS nondiabetic subjects significant changes metabolic hormonal parameter basal state clamp slight reduction body weight kg diabetic patients significant changes body weight basal plasma insulin levels blood glucose levels mM plasma free fatty acid concentrations microM d-fenfluramine placebo clamp insulin metabolic clearance rate MCR similar placebo d-fenfluramine endogenous hepatic glucose production suppressed whereas glucose disposal d-fenfluramine average increase glucose MCR CONCLUSIONS mechanism treatment d-fenfluramine induces blood control insulin sensitivity obese patients NIDDM independent significant weight reduction last effect present obese subjects normal oral glucose tolerance